MolecularMD Withdraws PMA for Leukemia CDx | GenomeWeb

NEW YORK (GenomeWeb News) – MolecularMD and Ariad Pharmaceuticals today said that MolecularMD has withdrawn its premarket approval application to the US Food and Drug Administration for its BCR-ABL T315I Mutation Test.

MolecularMD's test detects the BCR-ABL T315I mutation in chronic myeloid leukemia and Philadephia-chromosome positive acute lymphoblastic leukemia patients and was intended as a companion diagnostic for Ariad's investigational BCR-ABL inhibitor, ponatinib, currently being reviewed by FDA.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.